<DOC>
	<DOC>NCT00536770</DOC>
	<brief_summary>The purpose of this study is to determine the safety and efficacy of an investigational study drug DN-101 (calcitriol) when given in combination with gemcitabine ± erlotinib in the treatment of pancreatic cancer.</brief_summary>
	<brief_title>A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Histologically or cytologically confirmed diagnosis of locally advanced and unresectable, or metastatic pancreatic cancer Performance status 0, 1,or 2 Adequate bone marrow, renal and hepatic function Prior chemotherapy or radiation therapy for pancreatic cancer Prior treatment for other cancers in last 6 months Cancer of the brain or spine Active uncontrolled infection Hypercalcemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>